- Home
- CRGX vs AMBC Comparison
CRGX vs AMBC Comparison
Compare CRGX & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- AMBC
- Stock Information
- Founded
- CRGX 2021
- AMBC 1971
- Country
- CRGX United States
- AMBC United States
- Employees
- CRGX N/A
- AMBC N/A
- Industry
- CRGX
- AMBC Property-Casualty Insurers
- Sector
- CRGX
- AMBC Finance
- Exchange
- CRGX Nasdaq
- AMBC Nasdaq
- Market Cap
- CRGX 190.0M
- AMBC 411.3M
- IPO Year
- CRGX 2023
- AMBC 1991
- Fundamental
- Price
- CRGX $4.46
- AMBC $7.19
- Analyst Decision
- CRGX Hold
- AMBC Strong Buy
- Analyst Count
- CRGX 7
- AMBC 1
- Target Price
- CRGX $4.67
- AMBC $15.00
- AVG Volume (30 Days)
- CRGX 502.9K
- AMBC 940.8K
- Earning Date
- CRGX 08-11-2025
- AMBC 08-04-2025
- Dividend Yield
- CRGX N/A
- AMBC N/A
- EPS Growth
- CRGX N/A
- AMBC N/A
- EPS
- CRGX N/A
- AMBC N/A
- Revenue
- CRGX N/A
- AMBC $253,912,000.00
- Revenue This Year
- CRGX $57.81
- AMBC N/A
- Revenue Next Year
- CRGX N/A
- AMBC $17.41
- P/E Ratio
- CRGX N/A
- AMBC N/A
- Revenue Growth
- CRGX N/A
- AMBC 125.08
- 52 Week Low
- CRGX $3.00
- AMBC $5.99
- 52 Week High
- CRGX $25.45
- AMBC $13.64
- Technical
- Relative Strength Index (RSI)
- CRGX 57.89
- AMBC 49.52
- Support Level
- CRGX $4.09
- AMBC $6.97
- Resistance Level
- CRGX $4.51
- AMBC $7.22
- Average True Range (ATR)
- CRGX 0.18
- AMBC 0.27
- MACD
- CRGX 0.00
- AMBC 0.06
- Stochastic Oscillator
- CRGX 77.18
- AMBC 90.79
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.